BRPI0411759A - uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga - Google Patents

uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga

Info

Publication number
BRPI0411759A
BRPI0411759A BRPI0411759-0A BRPI0411759A BRPI0411759A BR PI0411759 A BRPI0411759 A BR PI0411759A BR PI0411759 A BRPI0411759 A BR PI0411759A BR PI0411759 A BRPI0411759 A BR PI0411759A
Authority
BR
Brazil
Prior art keywords
ethanol
implants containing
plasticizer
active ingredients
subcutaneous implants
Prior art date
Application number
BRPI0411759-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrice Mauriac
Pierre Marion
Original Assignee
Mediolanum Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Pharmaceuticals Ltd filed Critical Mediolanum Pharmaceuticals Ltd
Publication of BRPI0411759A publication Critical patent/BRPI0411759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/141—Plasticizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
BRPI0411759-0A 2003-06-26 2004-06-24 uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga BRPI0411759A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001302A ITMI20031302A1 (it) 2003-06-26 2003-06-26 Uso di etanolo come plasticizzante per preparare impianti sottocutanei contenenti principi attivi termolabili dispersi in una matrice di plga.
PCT/EP2004/051226 WO2005000277A1 (en) 2003-06-26 2004-06-24 Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix

Publications (1)

Publication Number Publication Date
BRPI0411759A true BRPI0411759A (pt) 2006-08-08

Family

ID=30131301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411759-0A BRPI0411759A (pt) 2003-06-26 2004-06-24 uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga

Country Status (17)

Country Link
US (1) US8206621B2 (enExample)
EP (1) EP1638534B1 (enExample)
JP (1) JP2009513165A (enExample)
KR (1) KR101143771B1 (enExample)
CN (1) CN100509060C (enExample)
AT (1) ATE398447T1 (enExample)
AU (1) AU2004251456B2 (enExample)
BR (1) BRPI0411759A (enExample)
CA (1) CA2530117C (enExample)
CY (1) CY1108346T1 (enExample)
DE (1) DE602004014496D1 (enExample)
ES (1) ES2308195T3 (enExample)
IT (1) ITMI20031302A1 (enExample)
MX (1) MXPA05013697A (enExample)
PL (1) PL1638534T3 (enExample)
PT (1) PT1638534E (enExample)
WO (1) WO2005000277A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
EP1909689A4 (en) * 2005-07-18 2011-11-16 Univ Pennsylvania PHARMACEUTICAL IMPLANTS AND METHOD OF USE THEREOF
ITMI20061539A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
DE602007008125D1 (de) 2006-10-31 2010-09-09 Surmodics Pharmaceuticals Inc Kugelförmige polymer-teilchen
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
US9498431B2 (en) * 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
CA2804035A1 (en) * 2010-06-30 2012-01-05 Evonik Degussa Corporation Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
CN103623415B (zh) * 2013-12-04 2015-03-25 北京诺康达医药科技有限公司 一种用于生物多肽制剂的plga与乙醇的复合物
EP3177319A1 (en) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Compacted solid dosage form
GB201702475D0 (en) * 2017-02-15 2017-03-29 Locate Therapeutics Ltd Tissue scaffold and scaffold composition
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0549629A (ja) * 1991-08-23 1993-03-02 Konica Corp 医用放射線画像読影装置
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
CN100446809C (zh) 2001-11-14 2008-12-31 阿尔扎有限公司 可注射的长效组合物

Also Published As

Publication number Publication date
PT1638534E (pt) 2008-09-29
EP1638534B1 (en) 2008-06-18
CA2530117C (en) 2012-01-10
MXPA05013697A (es) 2006-05-17
DE602004014496D1 (de) 2008-07-31
KR101143771B1 (ko) 2012-05-11
KR20060079146A (ko) 2006-07-05
WO2005000277A1 (en) 2005-01-06
AU2004251456A1 (en) 2005-01-06
AU2004251456B2 (en) 2009-12-03
US20060171987A1 (en) 2006-08-03
US8206621B2 (en) 2012-06-26
CY1108346T1 (el) 2014-02-12
EP1638534A1 (en) 2006-03-29
ITMI20031302A0 (it) 2003-06-26
CN1812770A (zh) 2006-08-02
JP2009513165A (ja) 2009-04-02
ES2308195T3 (es) 2008-12-01
PL1638534T3 (pl) 2009-02-27
ITMI20031302A1 (it) 2004-12-27
CA2530117A1 (en) 2005-01-06
CN100509060C (zh) 2009-07-08
HK1089954A1 (en) 2006-12-15
ATE398447T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
BRPI0411759A (pt) uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga
TR199903315T2 (xx) Kat� paroksetin da��l�mlar�n�n imali i�in yeni proses.
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
BR0313539A (pt) Composições depósito de polìmero multimodais injetáveis e seus usos
BRPI0516463A (pt) cánula escalonada e conjunto de cánula
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
AR064254A1 (es) Maiz extraido con solvente
BR9912275A (pt) Formulação de bioimplante
CL43546B (es) Compuesto derivado de tetrahidroquinolina con actividad moduladora del receptor fsh; composicion farmaceutica que contiene al compuesto; y uso del compuesto en la preparacion de medicamentos para la regulacion de la fertilidad.
BR0317186A (pt) Concentrado de anticongelamento e composição refrigerante aquosa pronta para o uso para sistemas de refriamento em acionadores de célula de combustìvel, e, usos de compostos e de um concentrado de anticongelamento
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
NO20066070L (no) Fremgangsmate for formulering av hurtig-dispergerende former omfattende minst et fiske gelatin valgt pa grunnlag av molekylvekt
BR0114839A (pt) composição, e método de liberação de uma substáncia ou um material eletroprocessado em um local desejado
AR031601A1 (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao
NO20024231L (no) Lipidb¶rer
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
BR0311965A (pt) Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
BRPI0606923A2 (pt) substáncia para uso como um medicamento, uso de uma substáncia, método de manufatura de uma substáncia para uso como um medicamento, formulação farmacêutica, e, método de manufatura de uma formulação farmacêutica
DE50114335D1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
BR0312179A (pt) Processo para preparação de derivado de epik5-n-o-supersulfato, composição farmacêutica e composição cosmética contendo o mesmo e seu uso
BRPI0611813A2 (pt) mÉtodo de uso de antagonistas de zonulina para prevenir a perda de ou para regenerar cÉlulas pancreÁticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2311 DE 22-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.